Abstract Library

#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma

Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.

Conference:

Presenting Author: Zhang L

Authors: Falkman L, Zhang L, Welin S, Crona J,

Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,

#4103 The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation

Introduction: Tumor evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumors (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease.

Conference:

Presenting Author: Crona J

Authors: Backman S, Botling J, Nord H, Ghosal S, Stålberg P,

Keywords: Pancreatic neuroendocrine tumor, Tumor evolution, Alkylating chemotherapy, Treatment resistance,

#3810 A patient with BRAF V600E mutated colon-NEC showing response to BRAF- and MEK inhibitors

Introduction: Preclinical studies have reported that the BRAF V600E mutation is a druggable target in colorectal neuroendocrine carcinomas (NECs). At least one case report has presented clinical success in the treatment of colorectal NEC using a BRAF inhibitor.

Conference:

Presenting Author:

Authors: Falkman L, Sundin A, Crona J, Wallin G, Welin S,

Keywords: neuroendocrine carcinoma, BRAF V600E, dabrafenib, trametinib, colorectal nec,

#3106 Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment

Introduction: Selection of third-line treatment after somatostatin analogues (SSA) and Peptide Receptor Radionuclide Therapy (PRRT) for WD-SiNETs remains challenging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Cives M, de Mestier L, Crona J, Spada F,

Keywords: small bowel, well-differentiated, third-line, everolimus, IFN, chemotherapy, liver embolisation, multidisciplinary, survey, decision making,

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,